Literature DB >> 11789493

Cyclophosphamide therapy in a serious case of lupus nephritis during pregnancy.

H Kart Köseoglu1, A E Yücel, G Künefeci, F N Ozdemir, H Duran.   

Abstract

Systemic lupus erythematosus (SLE) flare is common, and renal involvement is one of the most serious problems during pregnancy. Aggressive immunosuppressive therapy should be considered for patients with diffuse proliferative lupus nephritis. These individuals are at high risk for progression to end-stage renal disease. Immunosuppressive drugs can cause significant toxic and teratogenetic effects. In this report, we describe the case of a pregnant patient with lupus nephritis who was treated with cyclophosphamide. The patient was in the second trimester of her first pregnancy and did not respond to corticosteroid therapy. She underwent intensive in-hospital care while she was on cyclophosphamide therapy. Both mother and baby were well at delivery.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11789493     DOI: 10.1177/096120330101001110

Source DB:  PubMed          Journal:  Lupus        ISSN: 0961-2033            Impact factor:   2.911


  6 in total

1.  Successful twin pregnancy while on cyclophosphamide therapy in a patient with lupus nephritis.

Authors:  Rajiva Gupta; S Deepanjali; M M Thabah; P Kaur; S Gupta
Journal:  Rheumatol Int       Date:  2009-01-24       Impact factor: 2.631

Review 2.  The management of rheumatic diseases in pregnancy.

Authors:  K Mitchell; M Kaul; Megan E B Clowse
Journal:  Scand J Rheumatol       Date:  2010-03       Impact factor: 3.641

Review 3.  Pharmacological Approach to Managing Childhood-Onset Systemic Lupus Erythematosus During Conception, Pregnancy and Breastfeeding.

Authors:  Nicole Bitencourt; Bonnie L Bermas
Journal:  Paediatr Drugs       Date:  2018-12       Impact factor: 3.022

Review 4.  Lupus activity in pregnancy.

Authors:  Megan E B Clowse
Journal:  Rheum Dis Clin North Am       Date:  2007-05       Impact factor: 2.670

Review 5.  New insights into pregnancy-related complications in systemic lupus erythematosus.

Authors:  Doruk Erkan; Lisa Sammaritano
Journal:  Curr Rheumatol Rep       Date:  2003-10       Impact factor: 4.592

Review 6.  Human pregnancy safety for agents used to treat rheumatoid arthritis: adequacy of available information and strategies for developing post-marketing data.

Authors:  Christina D Chambers; Zuhre N Tutuncu; Diana Johnson; Kenneth L Jones
Journal:  Arthritis Res Ther       Date:  2006       Impact factor: 5.156

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.